Welcome to our dedicated page for Korro Bio news (Ticker: KRRO), a resource for investors and traders seeking the latest updates and insights on Korro Bio stock.
Korro Bio, Inc. develops genetic medicines based on RNA editing for rare and highly prevalent diseases. The company uses its OPERA® oligonucleotide promoted editing of RNA platform to design therapies that harness endogenous RNA editing for precise, transient single-base edits.
Korro Bio news commonly covers corporate updates, financial results, scientific presentations, investor conference activity, and pipeline progress. Recurring program topics include KRRO-121 for hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research for alpha-1 antitrypsin deficiency, private placement financings, equity-inducement grants, and other capital-structure and governance updates.
Korro Bio (Nasdaq: KRRO) has received approval from Australian HREC and TGA clearance to begin a Phase 1/2a clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD). The REWRITE study will evaluate safety, tolerability, and pharmacological aspects of KRRO-110 at various doses. The company plans to dose the first participant in Q1 2025, with an interim readout expected in H2 2025 and study completion in 2026. Previous testing in PiZZ genotype mouse models showed >60% editing and therapeutically relevant levels of functional M-AAT secretion.
Korro Bio (Nasdaq: KRRO) has announced its participation in the Jefferies London Healthcare Conference. CEO and President Ram Aiyar will deliver a presentation on November 19, 2024, at 8:00 a.m. GMT, accompanied by CFO Vineet Agarwal and Chief Medical Officer Kemi Olugemo. The company, which specializes in developing RNA-editing genetic medicines for rare and prevalent diseases, will provide a live webcast of the presentation through their website. A replay will be available for 30 days following the event.
Korro Bio (Nasdaq: KRRO) reported its third quarter 2024 financial results and provided business updates. Significant milestones include the submission of a regulatory filing for the first-in-human clinical study of KRRO-110 for alpha-1 antitrypsin deficiency (AATD), the formation of a Clinical Advisory Board (CAB), and a partnership with Novo Nordisk to develop RNA editing therapies for cardiometabolic diseases. As of September 30, 2024, Korro's cash position was $169.1 million, providing a cash runway into the second half of 2026. R&D expenses increased to $16.0 million from $14.0 million in the same period in 2023, and G&A expenses rose to $7.3 million from $5.1 million. The net loss for the quarter was $21.0 million, compared to $18.5 million in the prior year.
Korro Bio (Nasdaq: KRRO) has submitted a regulatory filing to Australia's Bellberry HREC for a Phase 1/2 clinical study of KRRO-110, targeting Alpha-1 Antitrypsin Deficiency (AATD). The company has formed a Clinical Advisory Board comprising distinguished lung and liver experts to guide the clinical development strategy. First participant dosing is planned for Q1 2025, with an interim readout expected in H2 2025 and study completion anticipated in 2026. The company reports having a strong balance sheet to support the completion of the Phase 1/2 study and advance additional programs.
Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company developing RNA-editing genetic medicines, announced presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, October 6-9, 2024. The company will deliver one oral and two poster presentations.
The oral presentation, by Dr. Venkat Krishnamurthy, Senior VP and Head of Platform, will focus on KRRO-110, Korro's first development candidate for alpha-1 antitrypsin deficiency (AATD). This inherited disorder is caused by single nucleotide variants in the SERPINA1 gene.
The two poster presentations will cover:
- Purification of Human ADAR for evaluating oligo-directed RNA editing
- Using ADAR1 chimeric eCLIP to understand on-target and off-target behaviors of RNA editing oligonucleotides
Korro Bio (Nasdaq: KRRO) has announced a collaboration with Novo Nordisk to develop two therapeutic candidates using Korro's proprietary OPERA™ platform for RNA editing. The partnership, initially focusing on cardiometabolic diseases, has a total deal value of up to $530 million in upfront, development, and commercial milestone payments, plus tiered royalties and R&D funding.
The collaboration combines Novo Nordisk's expertise in cardiometabolic diseases with Korro's RNA editing technology to potentially address undruggable targets. Korro's OPERA platform aims to modify mRNA without altering DNA, offering a pharmacologically titratable approach to genetic medicine. Korro will advance up to two programs through preclinical development, after which Novo Nordisk may progress them to clinical studies.
Korro Bio (Nasdaq: KRRO), a biopharmaceutical company developing RNA-editing genetic medicines, has announced its participation in two upcoming investor conferences. At the 2024 Cantor Global Healthcare Conference on September 17, COO Todd Chappell will engage in a fireside chat, while CFO Vineet Agarwal will attend investor meetings. At Chardan's 8th Annual Genetic Medicines Conference on September 30, CEO and President Ram Aiyar will participate in a fireside chat, with Agarwal also in attendance.
Both fireside chats will be webcast live and accessible through Korro's website, with replays available for 30 days post-event. These conferences provide Korro an opportunity to showcase its innovative approach to genetic medicine and engage with investors.
Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company focused on RNA editing for rare and prevalent diseases, has announced significant changes to its Board of Directors. Dr. Katharine Knobil, an industry veteran with over 25 years of experience, has been appointed as an Independent Director. Dr. Knobil brings extensive expertise in clinical development and regulatory affairs, having held key positions at Agilent Technologies, Kaleido Biosciences, and GlaxoSmithKline.
Simultaneously, David Lucchino has stepped down from the Board. Dr. Ram Aiyar, CEO and President of Korro, expressed enthusiasm about Dr. Knobil's appointment, highlighting her valuable experience as the company advances its innovative pipeline. Dr. Knobil shared her excitement about joining Korro and contributing to the advancement of RNA editing technology.
Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company developing RNA-editing genetic medicines, announced its participation in several upcoming investor and scientific conferences in September 2024. These include:
1. 2024 Wells Fargo Healthcare Conference (Sept. 4): 1x1 investor meetings
2. RNA Leaders USA Congress (Sept. 5): Presentation on OPERA™ platform
3. H.C. Wainwright 26th Annual Global Investment Conference (Sept. 9): Company presentation
4. ISCTM 2024 Autumn Conference (Sept. 12): Session on neurophysiological markers
The H.C. Wainwright presentation will be webcast live and available for replay on Korro's website for 30 days.
Korro Bio (NASDAQ: KRRO) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Regulatory filing for KRRO-110 in alpha-1 antitrypsin deficiency (AATD) expected in H2 2024.
2. Preclinical data presented at ATS 2024 showed KRRO-110's ability to correct AAT protein, resulting in >70% M-AAT in circulation.
3. Q2 2024 ended with $187.8 million in cash, cash equivalents, and marketable securities.
4. Cash runway extended into H2 2026, funding KRRO-110 FIH trial completion and pipeline advancement.
5. Q2 2024 financial results: R&D expenses $17.1 million, G&A expenses $7.0 million, net loss $21.8 million.
6. Interim Phase 1/2 clinical trial readout for KRRO-110 in ZZ AATD patients expected in H2 2025.